Membership

Our members receive our quarterly e-newsletter with members-only content including interviews with dermatologists, information on contests and draws, and are the first to hear about upcoming events.

Membership is free.

Learn More

Etanercept (TNF Blocker)

How Does It Work?

Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
50 mg twice weekly for 3 months, then 50 mg once weekly thereafter

For psoriatic arthritis: 
50 mg once weekly

What Are The Possible Side Effects?

The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.

Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Etanercept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsetanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. Note: all requests for etanercept for patients weighing 63 kg or more will be assessed for
coverage with an etanercept biosimilar. Enbrel will be approved for new etanercept starts for pediatric patients weighing less than 63 kg.
No 
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation 
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis.Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes – L/UNo 
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. Yes –S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. 
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes - EDS ; all new etanercept patients will be covered for Brenzys or ErelziYes – EDS; all new etanercept patients will be covered for Erelzi 
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes- Only for clients who received approval for Enbrel before October 2, 2017
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/AYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
YukonBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
NIHBBiologics and BiosimilarsEtanerceptErelzi™NoYes- L/U
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®NoNo
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoNo
YukonBiologics and BiosimilarsEtanerceptBrenzys®NoYes – EDS
NIHBBiologics and BiosimilarsEtanerceptBrenzys®NoNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi): Call 1-844-27XPOSE (1-844-279-7673) for information

Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf

Adalimumab (TNF Blocker)

How Does It Work?

Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose

For psoriatic arthritis:
40 mg every other week

What Are The Possible Side Effects?

The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.

Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022.Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022.
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab.Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab.
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis.Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - L/UNo
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.
New BrunswickBiologics and BiosimilarsAdalimumabHumira®No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before December 15, 2021Yes- only for clients who received approval for Humira before December 15, 2021
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before June 11, 2021Yes- only for clients who received approval for Humira before June 11, 2021
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHadlima®NoNo
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabAbriladaNoNo
AlbertaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
OntarioBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbriladaNoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
NunavutBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
YukonBiologics and BiosimilarsAdalimumabAbriladaNoNo
NIHBBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsAdalimumabSimlandiNoNo
AlbertaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
OntarioBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabSimlandiYes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabSimlandiNoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
NunavutBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabSimlandiNoNo
NIHBBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabYuflymaNoNo
AlbertaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
OntarioBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabYuflymaNoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflymaNoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflymaNoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
NunavutBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabYuflymaNoNo
NIHBBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

https://abbviecare.ca/

Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html

Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com

Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca

Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca

Hulio
Phone: 1-844-485-4677 | Email hulio@assistprogram.com

Infliximab (TNF Blocker)

How Does It Work?

Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.

For plaque psoriasis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter

For psoriatic arthritis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.

What Are The Possible Side Effects?

The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.

Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®NoNo 
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo 
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
OntarioBiologics and BiosimilarsInfliximabRemicade®No. May be covered through EAP in specific clinical circumstances .No. May be covered through EAP in specific clinical circumstances .
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsInfliximabRemicade®No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. 
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNo
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.
NIHBBiologics and BiosimilarsInfliximabRemicade®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabAvsola®NoNo
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - EDSYes - EDS
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsInfliximabOmvyence™No records available on NIHB websiteNo records available on NIHB website
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNo
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabRemsima™No records available on NIHB websiteNo records available on NIHB website
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/

Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.cawww.avsola.ca

Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/

Certolizumab pegol (TNF Blocker)

How Does It Work?

Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).

Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Certolizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
400 mg every 2 weeks

For psoriatic arthritis:
400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks

What Are The Possible Side Effects?

The most common side effects of certolizumab include joint pain, and an increased risk of  upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.

Certolizumab should be avoided in patients with moderate to severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsCertolizumab pegolCimzia®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
ManitobaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
OntarioBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EAP
QuebecBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
New BrunswickBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Nova ScotiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
NunavutBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
YukonBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
NIHBBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

UCB Cares 1-800-908-5555

Golimumab (TNF Blocker)

How Does It Work?

Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).

How Is It Used?

Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.

Golimumab should be avoided in patients with severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
OntarioBiologics and BiosimilarsGolimumabSimponi®N/ANo – EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Ixekizumab (IL17 Blocker)

How Does It Work?

Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ixekizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks

For psoriatic arthritis:
160 mg once, followed by 80 mg every 4 weeks

What Are The Possible Side Effects?

The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.

Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UNo 
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsIxekizumabTaltz®NoNo
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Call 1-877-219-8908 for information.

Brodalumab (IL17 Blocker)

How Does It Work?

Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.

How Is It Used?

Brodalumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks

What Are The Possible Side Effects?

The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.

Brodalumab should be avoided in patients with Crohn’s disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSNo
ManitobaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/Us.o.
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
YukonBiologics and BiosimilarsBrodalumabSiliq™NoN/A
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Call 1-844-852-6967 for information.

Secukinumab (IL17 Blocker)

How Does It Work?

Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Secukinumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks

For psoriatic arthritis:
For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

What Are The Possible Side Effects?

The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.

Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UNo 
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes - EDS
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Ustekinumab (IL12/23 Blocker)

How Does It Work?

Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.

For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

For psoriatic arthritis:
45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

What Are The Possible Side Effects?

The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDSNo
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Risankizumab (IL23 Blocker)

How Does It Work?

Risankizumab is a biologic that targets the overactive immune system in psoriasis. Risankizumab works by supressing interleukin-23A.

How Is It Used?

The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. 

What Are The Possible Side Effects?

The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

N/A

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSNo
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/A N/A
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Guselkumab (IL23 Blocker)

How Does It Work?

Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.

How Is It Used?

Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.

For plaque psoriasis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

For psoriatic arthritis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.

Patients should be screened for tuberculosis and infections prior to treatment.

Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.

If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.

 

What Medications Interact With This Treatment?

For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

 

 

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
AlbertaBiologics and BiosimilarsGuselkumabTremfya®NoNo
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsGuselkumabTremfya®NoNo
OntarioBiologics and BiosimilarsGuselkumabTremfya®NoNo
QuebecBiologics and BiosimilarsGuselkumabTremfya®NoNo
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®NoNo
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®NoNo
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsGuselkumabTremfya®NoNo
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo
NIHBBiologics and BiosimilarsGuselkumabTremfya®NoNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Health Canada Product Monograph
https://pdf.hres.ca/dpd_pm/00057930.PDF

Abatacept

How Does It Work?

Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.

How Is It Used?

Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.

Abatacept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNo
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNo
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNo
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNo
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo. EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNo
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNo
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNo
YukonBiologics and BiosimilarsAbataceptOrencia®NoNo
NIHBBiologics and BiosimilarsAbataceptOrencia®NoNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Tildrakizumab

How Does It Work?

Ilumya™ acts on specific molecular signals used by the immune system to decrease the immune system’s overactivity that can contribute to plaque psoriasis.

How Is It Used?

Ilumya™ is a drug taken by injection often in 12-week intervals.

What Are The Possible Side Effects?

Side effects of Ilumya™ can include diarrhea, skin irritation and muscle pain at the injection site, fatigue, increased risk of infection, joint pain, and headaches. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.

Any Other Important Considerations?

Not applicable

What Medications Interact With This Treatment?

Certain vaccines cannot be taken while on Ilumya™. Talk to your doctor before being vaccinated to confirm it is safe to do so while on Ilumya. Ilumya may also interact with dextromethorphan. Ask your doctor or pharmacist if you are concerned about a drug interaction.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsTildrakizumabCyclosporine?NoN/A
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/A
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/A
OntarioBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
NunavutBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
YukonBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
NIHBBiologics and BiosimilarsTildrakizumabIlumya™NoN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Last updated November, 2021